Related Experiment Video
Updated: Jan 16, 2026

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
Published on: November 7, 2017
Kidney involvement and anemia in COVID-19 infection
Guido Gembillo1, Luigi Peritore2, Giuseppe Spadaro2
1Unit of Nephrology and Dialysis, AOU "G. Martino", University of Messina, Messina 98125, Sicilia, Italy. ggembillo@gmail.com.
Abstract:
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for coronavirus disease 2019 (COVID-19), has infected > 700 million people and led to > 7 million deaths worldwide. Although COVID-19 primarily affects the lungs, it can also affect the kidneys through various pathways. SARS-CoV-2 affects the kidney via several common mechanisms, such as dysregulation of angiotensin-converting enzyme 2, transmembrane serine protease 2 and tissue proteinase L expression in kidney tissue. People with chronic kidney disease (CKD) and COVID-19 have an increased risk of mortality and hospitalization in the intensive care unit. Anemia, a common consequence of CKD, is also associated with worsening outcomes in COVID-19 patients. In these patients with multiple comorbidities, there is a sharp increase in D-dimers, inflammatory parameters, creatinine and blood urea nitrogen. COVID-19 patients also present with resistance to erythropoietin (EPO)-stimulating agents, which necessitates elevated dosages even several months post-infection. In CKD, anemia is exacerbated by decreased EPO production, red blood cell (RBC) fragmentation due to impairment of the renovascular endothelium in situations such as glomerulopathy and malignant hypertension. Other factors include iron and/or folic acid deficiency, bleeding due to platelet dysfunction, inflammation, reduced RBC lifespan, poor iron utilization, uremia, and atypical blood loss after dialysis. Excessive hepcidin synthesis impairs the absorption of dietary iron and the mobilization of iron from endogenous reserves, thus contributing significantly to anemia and poor iron regulation in CKD. These findings suggest that CKD may contribute to the occurrence of anemia in COVID-19 patients, especially in older people with comorbidities. Our review aims to explore the complex relationship between CKD, COVID-19 and anemia to improve our understanding of the underlying mechanisms of the disease and the potential cofactors that worsen outcomes in these patients.
Insights
Chronic kidney disease (CKD) exacerbates anemia in COVID-19 patients, increasing mortality risk. Understanding the interplay between CKD, SARS-CoV-2 infection, and anemia is crucial for improving patient outcomes.
Area of Science:
- Nephrology
- Infectious Diseases
- Hematology
Background:
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19, impacting lungs and kidneys.
- Chronic kidney disease (CKD) patients with COVID-19 face higher mortality and ICU admission risks.
- Anemia, common in CKD, worsens COVID-19 outcomes and is linked to increased inflammatory markers and creatinine.
Purpose of the Study:
- To explore the complex relationship between CKD, COVID-19, and anemia.
- To elucidate the underlying mechanisms contributing to anemia in COVID-19 patients with CKD.
- To identify cofactors that exacerbate adverse outcomes in this patient population.
Main Methods:
- Review of existing literature on SARS-CoV-2, kidney disease, and anemia.
- Analysis of common mechanisms linking COVID-19 and kidney injury, including ACE2 and TMPRSS2 dysregulation.
- Examination of factors contributing to anemia in CKD, such as reduced erythropoietin (EPO) production and iron metabolism disruption.
Main Results:
- COVID-19 patients exhibit resistance to erythropoietin-stimulating agents.
- CKD contributes to anemia through decreased EPO, RBC fragmentation, iron deficiency, inflammation, and impaired iron utilization.
- Excessive hepcidin synthesis in CKD impairs iron absorption and mobilization, worsening anemia and iron regulation.
Conclusions:
- CKD significantly contributes to anemia development in COVID-19 patients, particularly those with comorbidities.
- The interplay between CKD, COVID-19, and anemia necessitates a comprehensive understanding for improved clinical management.
- Further research is needed to address the multifaceted mechanisms and cofactors influencing outcomes in these vulnerable patients.
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury I: Introduction
Chronic Kidney Disease III: Interprofessional Care

